Montreal, October 20, 2016 – Desjardins Innovatech, through its CTS program, recently invested $ 250,000 in Optina and its early diagnosis of illnesses. The Optina team has developed a simple eye scan to identify specific molecules associated with Alzheimer’s, diabetes and cardiovascular diseases. In addition, the technology keeps the usual functions that are used by the clear majority of ophthalmologists and optometrists.

“The CTS has allowed us to increase our funding round by contributing directly by accelerating the commercialization of our products, while adding concrete targets and key support to increase the value of our business,” said David Lapointe, President of Optina. Thanks to the investment made, we will be able to set up a sales force to boost the marketing and conquer this market of more than 50 billion dollars.

“Optina’s ability to innovate in the accessibility and quality of diagnostics makes it a solid undertaking, added Guillaume Hervé, Chairman of CTS. It is in this direction that the CTS program with Desjardins – Innovatech wants to continue to invest and increase the development of innovation in medical technologies. ”

The camera allows an accessible, fast and low-cost screening. Indeed, the Optina technique is carried out in a single visit, does not require the administration of external tastes and can be used on patients who have been operated on for cataracts. Moreover, it can detect other pathologies, which allows the company to increase its offer of services. The company seeks to promote its technology to pharmaceutical companies and researchers involved in the development of therapies for Alzheimer’s, but also around ophthalmology and optometry clinics as well as general practitioners and specialists in the disease, Alzheimer’s disease.

 

About Optina

Optina Diagnostics develops and markets medical diagnostic tests, using a simple and fast hyperspectral photography of the retina, with a first application in screening for Alzheimer’s disease. Our technology allows early identification of Alzheimer’s disease that facilitate the detection and diagnosis of disease in at-risk patients. Optina’s technology will help facilitate the development of drugs to treat this terrible disease.

 

About CTS

CTS is an accelerator of companies in the field of medical technologies which offers them to develop faster and increases their chances of success. The goal of the CTS is to offer start-up companies a unique proposition with structured framework that allows them to focus on developing their technology, reaching market dynamics and gaining the visibility they need to start and develop internationally.

 

About Desjardins – Innovatech

Created in 2005, the Desjardins – Innovatech fund was created by the initiative of the Government of Québec and Capital régional et coopératif Desjardins. With more than $ 55 million invested in nearly 40 companies and funds, Desjardins – Innovatech’s main mission is to promote and support companies from Quebec, who involved in the development of technological innovation or Industrialists and the new generation of Quebec innovation entrepreneurs, with their capital financing. In order to fulfill its mission, the fund joins forces with other players in the technological field – specialized investment funds, entrepreneurs, financial angels, technological company’s accelerators – contributing to increase PME in terms of job creation and economic development.

For additional information (journalists only)

Optina

David Lapointe

President

438-828-1675

info@optinadx.com

 

CTS

Romain Lortille Bruel

Director of Business Development

514-274-1001 or 514-808-9775

Lortillebruel@ctssante.ca

 

Desjardins – Innovatech 

Richard Lacasse

Media spokesperson

418-835-8444 or 1-866-835-8444, ext. 556 3163

Media@desjardins.com

Menu